VK2735 is an investigational, once-weekly injectable dual GIP/GLP-1 receptor agonist developed by Viking Therapeutics for obesity. The Phase 2 VENTURE trial reported up to 14.7% weight loss at 13 weeks. It is not currently FDA approved and is not legitimately sold as a research-peptide vial.
VK2735 is an investigational, once-weekly injectable dual GIP/GLP-1receptoragonist developed by Viking Therapeutics for obesity, with an oral formulation also in development. It is not currently FDA approved, no vial or reconstitution data has been published for human dosing, and no legitimate research-peptide vendor sells it, the figures below describe published Phase 2 clinical trial results, not a consumer or research protocol.
Peptide calculator
Storage Stability
Lyophilized
~1 year
Reconstituted
N/A (oral)
Room temp
Stable (capsule)
Mechanism of Action
Dual GIP/GLP-1 Receptor Agonism
VK2735 simultaneously activates both the GIPreceptor and the GLP-1 receptor, similar in concept to tirzepatide. Combined incretin receptor activation targets complementary appetite-suppression and insulin-sensitizing pathways, which Viking's Phase 2 data suggests produces weight loss comparable to other dual incretin agonists in this drug class.
Research Summary
VENTURE Phase 2 (NCT06068946)
Phase 2 Complete
Randomized, double-blind, placebo-controlled, parallel-arm trial, 176 adults with obesity/overweight and at least one weight-related comorbidity, 13 weeks, once-weekly subcutaneous. Mean weight loss: 9.1% at 2.5 mg, up to 14.7% at 15 mg, vs 1.7% with placebo. Published in Obesity (Silver Spring), 2026.
VANQUISH Phase 3
Active Research
Phase 3 VANQUISH-1 and VANQUISH-2 trials of weekly subcutaneous VK2735 in obesity are fully enrolled and advancing as of mid-2026. An oral Phase 3 trial is expected to begin in Q4 2026.
Research Protocols
Goal
Dose
Frequency
Route
Phase 2 VENTURE reference
2.5 mg, 5 mg, 10 mg, or 15 mg once weekly
Weekly
Subcutaneous
Not yet approved. This is the published Phase 2 VENTURE trial arm design (NCT06068946), shown for research reference only, not a consumer protocol, vendor research-peptide recipe, or medical recommendation. VK2735 is not legitimately sold by any research-peptide vendor; the calculator below defaults to a placeholder vial, enter your own vial size and water volume.
Interactions
Safety Profile
The most common side effects reported in the VENTURE trial were mild-to-moderate gastrointestinal symptoms, consistent with other incretin-receptor agonists. No long-term human safety data exists yet; VK2735 remains in Phase 3 trials.